slides · global inventory
List
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 110,471
Current window 71,461-71,490
Pages 3,683
Rows per page 30
Component
71,461-71,490 of 110,471
177
The slide highlights a potential contradiction between marketing claims of 'no dependency' and reported withdrawal symptoms.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
204
The slide highlights a discrepancy between the drug's safety profile as presented and the real-world experience of a physician.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
215
The slide functions as a 'fraud-exposure' or 'villain-critique' framework, systematically dismantling the credibility of the clinical trial data.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
216
This slide serves as a critical audit of clinical trial integrity, focusing on statistical manipulation and poor trial design.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
219
The slide uses a 'villain' framing for the Epworth Sleepiness Scale to justify why it should not be used in the context of the research.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
220
The slide uses a critical tone to re-evaluate clinical trial data, highlighting the gap between statistical results and clinical meaningfulness.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
234
The slide details three specific statistical and methodological reasons for the FDA's rejection of the HARMONY 1 study.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
247
The slide serves as a qualitative research summary based on 16 expert interviews.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
248
This slide presents a series of critical findings regarding market performance, competitive positioning, safety concerns, and marketing practices for the drug Wakix.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
249
The slide presents qualitative interview summaries as evidence of poor market reception.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
252
The slide presents qualitative interview data from four distinct medical professionals, highlighting skepticism, lack of efficacy, and safety concerns.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
256
The slide uses direct quotes from a physician to highlight low adoption and skepticism.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
260
The slide uses a Q&A format to validate the negative sentiment expressed in the summary header.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
264
Includes direct quotes from the physician regarding his clinical experience and frustrations with insurance paperwork.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
265
The slide uses a Q&A format to expose the physician's aggressive prescribing behavior and lack of clinical rigor.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
277
The slide uses a Q&A format to validate the prescriber's credentials and patient volume.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
281
The slide presents a transcript of an interview with a physician, highlighting negative clinical experience.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
287
The slide uses a Q&A format to provide evidence for the summary points listed in the title.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
320
The slide uses highlighted text to emphasize key admissions regarding prescription volume and the criminal nature of the speaker program.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
325
The slide uses a 'fraud-exposure' narrative by contrasting the official label with market reality.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
327
The slide uses a Q&A transcript format to expose potentially fraudulent sales practices.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
328
The slide uses highlighted text to emphasize key allegations regarding pressure and compensation.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
331
The slide uses a Q&A format to highlight discrepancies in prescription volumes across similar-sized territories.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
338
Includes direct Q&A transcript excerpts highlighting the alleged lack of transparency and short-term focus.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
342
The slide uses a Q&A format to build a case for regulatory or ethical misconduct.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
344
The slide uses a Q&A format to expose a scheme where management facilitates off-label marketing.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
346
The slide uses a Q&A transcript format to substantiate claims of unethical sales practices.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
363
The slide uses a Q&A format to validate the thesis of a slowing business.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
01
The slide serves as a cover page for an activist short report, utilizing strong, accusatory language to frame the company as a fraudulent entity.Lasertec Corporation (6920) · Scorpion Capital
Activist deck Short seller Beat · Introduction to Lasertec1 hit
04
The slide serves as an executive summary of the investigative findings presented in the deck.Lasertec Corporation (6920) · Scorpion Capital
Activist deck Short seller Beat · Introduction to Lasertec1 hit